Stay updated on Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page.

Latest updates to the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new revision entry (v3.4.2) was added to the history, and an old government-funding/operating-status notice was deleted.SummaryDifference0.6%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding was added, and the revision history now shows v3.4.1 replacing v3.4.0. These updates are informational and do not affect study details, results, or user interactions; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check28 days agoChange DetectedUI enhancements to the history view include a Show glossary option and color-coded highlights for additions and deletions, along with updated revision labels (v3.4.0). These changes affect presentation only and do not modify the trial data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check42 days agoChange DetectedFooter revision updated from v3.3.3 to v3.3.4; no substantive changes to study history or page content.SummaryDifference0.1%

- Check63 days agoChange Detected- Added a new revision note 'Revision: v3.3.3' and removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' from the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check70 days agoChange DetectedNew sections Adverse Events, Outcome Measures, Participant Flow, Contacts/Locations, and Study Status were added in versions dated 2025-11-23 and 2025-12-11; a prior entry dated 2024-11-21 was removed.SummaryDifference0.7%

Stay in the know with updates to Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs Intravenous Atezolizumab in NSCLC Clinical Trial page.